CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 247 enrolled
Drug / intervention
PL2200 +1 moredrug
Likely dose
PL2200 325 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01646814
NCT01646814Phase 2Completed
CompareCT.gov

A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

PLx Pharma·interventional·Posted Jul 20, 2012·Updated Jun 7, 2022

In Brief

A Phase 2 clinical trial evaluating PL2200 and Aspirin tablets for Gastroduodenal Ulceration. Completed, enrolled 247 participants across 10 sites.

Detailed Summary

This trial is a Phase 2, randomized, controlled study to compare the degree of mucosal injury after the oral administration of an investigational product, PL2200, and a marketed 325 mg immediate-release aspirin product.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroduodenal Ulceration
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2012
Enrollment StartSep 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.0 years ago

Interventions

PL2200drug

PL2200, containing 325 mg aspirin active ingredient

Aspirin tabletsdrug

325 mg aspirin tablets (USP)